Aug 12, 2026 4:05pm EDT RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
Aug 11, 2026 8:30am EDT RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
Aug 13, 2026 1:30 pm EDT Jones Hosts: The Evolving Pancreatic Cancer Landscape: The Role of RenovoRx's TAMP Platform and Emerging Clinical Advances
